<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Technetium Tc-99m tetrofosmin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Technetium Tc-99m tetrofosmin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Technetium Tc-99m tetrofosmin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="86874" href="/d/html/86874.html" rel="external">see "Technetium Tc-99m tetrofosmin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15516542"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Myoview;</li>
<li>Myoview 30mL</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F15245908"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F15245985"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b740c041-12a4-4816-af63-70c3a9e1bd67">Myocardial perfusion imaging; ventricular function imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial perfusion imaging; ventricular function imaging:</b> IV: Dosage range: 5 to 33 mCi (185 to 1221 MBq). When rest and stress imaging are performed on the same day, administer a first dose of 5 to 12 mCi (185 to 444 MBq) followed by a second dose of 15 to 33 mCi (555 to 1221 MBq) ~1 to 4 hours later.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992031"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989336"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F15245999"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F15245941"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Hematologic &amp; oncologic: Leukocytosis (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal distress, allergic skin reaction, altered sense of smell, angina pectoris, burning sensation of mouth, dyspnea, fever, hypersensitivity reaction, hypertension, hypotension, metallic taste, skin rash, torsades de pointes, urticaria, ventricular arrhythmia, visual disturbance, vomiting</p></div>
<div class="block coi drugH1Div" id="F15245922"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed within the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F15245923"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including abdominal pain, anaphylaxis, bronchospasm, chest pain, coughing, cutaneous reactions, dyspnea, hypotension, tachycardia, and throat tightness, have occurred; emergency treatment should be immediately available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious adverse events: Arrhythmias, bronchoconstriction, cerebrovascular events, hypotension, and myocardial infarction (MI) have occurred due to pharmacologic agents used in conjunction with stress imaging. Appropriate measures for resuscitation should be available during use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary artery disease: Patients with known or suspected coronary artery disease should undergo continuous cardiac monitoring during diagnostic evaluation with technetium Tc 99m tetrofosmin; emergency cardiac treatment should be immediately available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Patients should be adequately hydrated prior to dosing; instruct patients to void frequently following administration to decrease radiation exposure to the bladder. Myocardial imaging may be done while patients are at rest and/or under pharmacologic stress conditions.</p></div>
<div class="block foc drugH1Div" id="F15516543"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myoview: Tetrofosmin 1.38 mg (5s) [to be combined with sodium pertechnetate Tc99m injection solution (not included)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myoview 30mL: Tetrofosmin 1.38 mg (5s) [to be combined with sodium pertechnetate Tc99m injection solution (not included)] [pyrogen free]</p></div>
<div class="block geq drugH1Div" id="F20452828"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F15246000"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Not for direct IV injection; only reconstituted technetium Tc 99m tetrofosmin may be administered IV See manufacturer's prescribing information for complete administration procedure. Ensure adequate hydration before and after administration; void frequently to minimize bladder exposure. Imaging may begin 15 minutes after administration.</p>
<p style="text-indent:0em;margin-top:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn and shielding should be used during handling and administration.</p></div>
<div class="block use drugH1Div" id="F15245910"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial perfusion imaging:</b> Radiopharmaceutical imaging agent used for myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular function imaging: </b>Radiopharmaceutical imaging agent used to assess left ventricular function including left ventricular ejection fraction and wall motion in patients with known or suspected heart disease.</p></div>
<div class="block mst drugH1Div" id="F15245904"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F15594483"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F15594481"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the diagnostic effect of Technetium Tc 99m Tetrofosmin.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53623772"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to use in women of reproductive potential (SNM 2010).</p></div>
<div class="block pri drugH1Div" id="F15245912"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (ACR/SPR 2018; Adelstein 1999; ICRP 2000; SNM 2010).</p></div>
<div class="block brc drugH1Div" id="F15245917"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m tetrofosmin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Although an interruption of breastfeeding may not always be required (ABM [Mitchell 2019]), expressing and discarding breast milk for a period of 4 hours following technetium Tc 99m tetrofosmin for myocardial perfusion imaging may be considered (IAEA 2018). The manufacturer recommends patients pump and discard breast milk for 60 hours after administration to decrease radiation exposure to the breastfed infant. Women can pump and store breast milk prior to the procedure, which can be bottle-fed (Harding 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">Elective diagnostic procedures should be delayed until breastfeeding has stopped (SNM 2010). Women who are breastfeeding and caring for individuals undergoing nuclear medicine procedures do not need any additional precautions (ABM [Mitchell 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994).</p></div>
<div class="block pha drugH1Div" id="F50148370"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radioactive diagnostic agent that decays by isomeric transition to emit a photon that can be detected by imaging.</p></div>
<div class="block phk drugH1Div" id="F15245960"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributed in the myocardium, blood, liver, and lung</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Physical half-life: 6.03 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Myocardium uptake: 5 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (40% of injected activity within 48 hours); feces (26% of injected activity within 48 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777233"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Myoview</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Myoview</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Myoview</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Myoview</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Myoview</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Myoview</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Myoview</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Myoview</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10331526">
<a name="10331526"></a>Adelstein SJ. Administered Radionuclides in Pregnancy. <i>Teratology</i>. 1999;59(4):236-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tetrofosmin-drug-information/abstract-text/10331526/pubmed" id="10331526" target="_blank">10331526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR–SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation (resolution 39). Revised 2018. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Pregnant-Pts.pdf?la=en. Accessed February 24, 2020.</div>
</li>
<li>
<div class="reference">
                  Harding LK, Bossuyt S, Pellet C, et al. Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers. <i>Eur J Nucl Med</i>. 1995;22(5)BP17.</div>
</li>
<li>
<div class="reference">
                  International Atomic Energy Agency. <i>IAEA Safety Standards for Protecting People and the Environment: Radiation Protection and Safety in Medical Uses of Ionizing Radiation. Specific Safety Guide No. SSG-46</i>. IAEA; 2018. https://www​.iaea.org​/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11108925">
<a name="11108925"></a>International Commission on Radiological Protection (ICRP). Pregnancy and Medical Radiation. <i>Ann ICRP</i>. 2000;30(1):iii-viii, 1-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tetrofosmin-drug-information/abstract-text/11108925/pubmed" id="11108925" target="_blank">11108925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107104">
<a name="31107104"></a>Mitchell KB, Fleming MM, Anderson PO, Giesbrandt JG; Academy of Breastfeeding Medicine. ABM Clinical Protocol #31: radiology and nuclear medicine studies in lactating women. <i>Breastfeed Med</i>. 2019;14(5):290‐294. doi:10.1089/bfm.2019.29128.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tetrofosmin-drug-information/abstract-text/31107104/pubmed" id="31107104" target="_blank">31107104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645546">
<a name="2645546"></a>Mountford PJ, Coakley AJ. A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations. <i>Nucl Med Commun</i>. 1989;10(1):15-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tetrofosmin-drug-information/abstract-text/2645546/pubmed" id="2645546" target="_blank">2645546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Myoview.1">
<a name="Myoview.1"></a>Myoview (technetium Tc99m tetrofosmin) [prescribing information]. Arlington Heights, IL: GE Healthcare Medi-Physics Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8162938">
<a name="8162938"></a>Rubow S, Klopper J, Wasserman H, et al. The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry. <i>Eur J Nucl Med</i>. 1994;21(2):144-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tetrofosmin-drug-information/abstract-text/8162938/pubmed" id="8162938" target="_blank">8162938</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Society of Nuclear medicine (SNM). Society of Nuclear Medicine procedure guideline for general imaging. Version 6.0. Revised 2010. http://s3.amazonaws.com/rdcms-snmmi/files/production/public/docs/General_Imaging_Version_6.0.pdf. Accessed July 22, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 86873 Version 81.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
